Abstract

Tuberculosis represents the main cause of mortality due to a single pathogen infection. Advances in anti-tuberculosis therapies are urgently required both for treatment of the 8-12 million new cases of tuberculosis leading to 2 million deaths each year, as well as for the 2 billion individuals already infected with M. tuberculosis, who are at the risk of developing disease. The present review summarizes the actually available information about currently existing therapies and perspectives for future innovative therapeutic approaches.

Keywords: tuberculosis, mycobacteria, therapeutics, immune-modulators